Breaking News

Cellular Biomedicine Expands into Arthritis Market

June 13, 2013

Gets IP go-ahead for Chinese market

Cellular Biomedicine Group, a biopharma firm engaged in the development of treatments for degenerative and cancerous diseases, plans to expand into the China Osteoarthritis and Rheumatoid Arthritis market. Following a complete analysis of current China patents by an intellectual property law firm, Cellular Biomedicine Group has clearance to pursue IP operation with respect to its patents for autologous and allogeneic adipose-derived stem cell compositions for the treatment of osteoarthritis and rheumatoid arthritis, as well as for various stem cell processing and preservation technologies.
 
Dr. Wei (William) Cao, president of Cellular Biomedicine Group, said, "In China there are 72.5 million people suffering from knee osteoarthritis (KOA), and 4.5 million suffering from rheumatoid arthritis (RA). We are very confident to enter the world's largest KOA and RA market with freedom of operation."

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems